Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

References

• Nestor JJ, Parkes D, Feigh M., et al. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Sci Rep. 2022;12:1. doi:10.1038/s41598-022-10577-2
   Web of Science ®Google Scholar
• Zhao F, Zhou Q, Cong Z, et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022;13:1. doi:10.1038/s41467-021-27699-2
   PubMed Web of Science ®Google Scholar
• van Ruiten CC, Smits MM, Kok MD, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21:1. doi:10.1186/s12933-022-01492-x
   Web of Science ®Google Scholar
• Bradley CL, McMillin SM, Hwang AY, et al. High-dose once-weekly semaglutide: a new option for obesity management. Ann Pharmacother. 2022;56(8):941–950. doi:10.1177/10600280211053867
   Web of Science ®Google Scholar
• Berkovic MC, Rezic T, Bilic-Curcic I, et al. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases. 2022;10(20):6759–6768. doi:10.12998/wjcc.v10.i20.6759
   Web of Science ®Google Scholar
• Chang Y-H, Hung H-Y. Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: a mini-review. Eur J Med Chem. 2022;237:114405. doi:10.1016/j.ejmech.2022.114405
   Web of Science ®Google Scholar
• Fabrizio Muratori F, Di Sacco VG, Di Sacco G, et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eating and Weight Disorders - Studies on Anorexia. Bulimia Obesity. 2022;1:292.
   Google Scholar
• Barboza JJ, Huamán MR, Melgar B, et al. Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2022;11:2998. doi:10.3390/jcm11112998
   PubMed Web of Science ®Google Scholar
• Alabduljabbar K, Al-Najim W, Carel W. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: a Focus on the STEP Trials. Nutrients. 2022;14:2217. doi:10.3390/nu14112217
   Web of Science ®Google Scholar
• Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192:E875–E891. doi:10.1503/cmaj.191707
   PubMed Web of Science ®Google Scholar
• Zhao Y, Jing D. Research progress of GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus. Geriatrics Res. 2021;2(03):55–60.
   Google Scholar
• American Diabetes Association. Introduction: standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S1–S2. doi:10.2337/dc22-Sint
   PubMedGoogle Scholar
• Two-year Research Study Investigating How Well Semaglutide Works in People Suffering from Overweight or Obesity (STEP 5). Available from: https://clinicaltrials.gov/ct2/show/NCT03693430?term=03693430&draw=2&rank=1. Accessed November 25, 2022.
   Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, Phase 3 trial. Lancet. 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Isendahl J, Khalid U, et al; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193–206. doi:10.1016/S2213-8587(22)00008-0
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: the STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138–150. doi:10.1001/jama.2021.23619
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. doi:10.1016/S2213-8587(17)30013-X
   PubMed Web of Science ®Google Scholar
• Altintas Dogan AD, Hilberg O, Hess S, et al. Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2022;17:405–414. doi:10.2147/COPD.S350133
   PubMed Web of Science ®Google Scholar
• Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719–1730. doi:10.1056/NEJMoa2028198
   PubMed Web of Science ®Google Scholar
• Gudbergsen H, Overgaard A, Henriksen M, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr. 2021;113(2):314–323. doi:10.1093/ajcn/nqaa328
   PubMed Web of Science ®Google Scholar
• Zobel EH, Ripa RS, von Scholten BJ, et al. Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu] DOTATATE. Diagnostics. 2021;11(8):1431. doi:10.3390/diagnostics11081431
   Web of Science ®Google Scholar
• Hygum K, Harsløf T, Jørgensen NR, et al. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone. 2020;132:115197. doi:10.1016/j.bone.2019.115197
   Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: the SCALE IBT Randomized Controlled Trial. Obesity. 2020;28(3):529–536. doi:10.1002/oby.22726
   PubMed Web of Science ®Google Scholar
• Feng W, Gao C, Bi Y, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9(8):800–809. doi:10.1111/1753-0407.12555
   PubMed Web of Science ®Google Scholar
• Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women with PCOS - Full Text View, Available from: https://clinicaltrials.gov/ct2/show/NCT03480022?term=03480022&draw=2&rank=1. Accessed November 25, 2022.
   Google Scholar
• Vedtofte L, Bahne E, Foghsgaard S, et al. One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. J Clin Med. 2020;9(10):3213. doi:10.3390/jcm9103213
   Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40(8):1310–1319. doi:10.1038/ijo.2016.52
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–1616. doi:10.1016/S0140-6736(09)61375-1
   PubMed Web of Science ®Google Scholar
• Liraglutide improves weight maintenance and weight loss in obese adults without diabetes after diet-induced weight loss: the SCALE™ 56-week randomized study. Available from: https://clinicaltrials.gov/ct2/show/NCT00781937?term=00781937&draw=2&rank=1. Accessed November 25, 2022.
   Google Scholar
• Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481. doi:10.1016/S0140-6736(08)61246-5
   PubMed Web of Science ®Google Scholar
• Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–388. doi:10.1111/dom.13082
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Xia L, Shen T, Dong W, et al. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis. Diabetes Res Clin Pract. 2021;177:108904. doi:10.1016/j.diabres.2021.108904
   PubMed Web of Science ®Google Scholar